Skip to content
Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation

Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation

Get the podcast

BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cance

The Audio Journal of Oncology

BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cancer Conference but also many patients could be advised to avoid chemotherapy and radiotherapy altogether after assessing their risk as “low” by using a combination of clinical and genetic risk scores, the study concluded.

Emiel Rutgers MD, PhD, a surgeon at the Netherlands Cancer Institute and professor of surgical oncology at the University of Amsterdam said MINDACT found an overall five-year loco-regional recurrence rate of only 2.1 per cent in patients treated conservatively and 2.5 per cent in those who had mastectomy. Tumor size and grade were the only independent risk factors and the results provided “the opportunity to prospectively study de-escalation of radiotherapy in women with low-risk early breast cancer”. He discussed his study and the clinical implications for the Audio Journal of Oncology.

Tags

70 gene signatureavoid radiotherapy in breast cancerbreast cancer risklow-risk breast cancerOncology

Next in EBCC 2018

All 6 interviews

Interview 5 of 6

Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY

Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY

BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2

30 March 2018
5 min